News

Simmunext Biotherapeutics to present at BioFit2024 Simmunext Biotherapeutics is proud to announce its presentation at BioFit2024, scheduled to be held on 3-4 December in Lille, France. As a leading biotechnology company dedicated to advancing the frontiers of immunotherapy, Simmunext is set to present its groundbreaking research and development initiatives on immunofilaments, aimed at revolutionizing the … Read more

Simmunext secures NWO Take-off Phase 2 funding.  Simmunext has secured funding from the Dutch Research Council (NWO) in the context of the Take-off Phase 2 program, which aims to stimulate and support activities and entrepreneurship towards applied sciences. The awarded project focuses on the application of immunofilaments (IF) in cancer. IF are proprietary polymers coupled … Read more

Simmunext will be presenting at the Radboudumc Investment Day Get ready for the third edition of Radboudumc Investment Day 2023 on October 12 in Nijmegen! Jointly organized by Radboudumc, Radboud University, Briskr and Oost NL, the Investment Day is a matchmaking event for investors, entrepreneurs and top researchers in the life sciences & health domain. … Read more

Financiering voor Simmunext: nieuwe therapie voor de behandeling van kanker. Met een investering vanuit het Vroege fase financiering Gelderland (VFF Gelderland) kan het Nijmeegse Simmunext Biotherapeutics BV verder met de ontwikkeling van een nieuwe behandeling voor kanker. Het bedrijf gebruikt de financiering om de werking van het medicijn verder te onderzoeken. Oost NL is fondsmanager … Read more

Radboudumc researchers publish on the scientific evidence for the inhibition of tumor growth and metastasis using immunofilaments in preclinical model systems.  Adoptive T cell therapy has successfully been implemented for the treatment of cancer. Nevertheless, ex vivo expansion of T cells by artificial antigen-presenting cells (aAPCs) remains cumbersome and can compromise T cell functionality, thereby … Read more